TY - CHAP A1 - Peter Johannes Holst A2 - Allan Randrup Thomsen ED1 - Ke Xu Y1 - 2011-07-20 PY - 2011 T1 - Harnessing the Potential of Adenovirus Vectored Vaccines N2 - The development of technologies that allow targeting of specific cells has progressed substantially in recent years for several types of vectors, particularly viral vectors, which have been used in 70% of gene therapy clinical trials. Particular viruses have been selected as gene delivery vehicles because of their capacities to carry foreign genes and their ability to efficiently deliver these genes associated with efficient gene expression. This book is designed to present the most recent advances in viral gene therapy BT - Viral Gene Therapy SP - Ch. 8 UR - https://doi.org/10.5772/22821 DO - 10.5772/22821 SN - PB - IntechOpen CY - Rijeka Y2 - 2020-09-19 ER -